ELBIT IMAGING LTD. ANNOUNCES CLOSING AND CONSUMMATION OF SALE OF
THE OPERATION OF "MANGO"
Tel Aviv, Israel, January 5, 2015, Elbit Imaging Ltd. (“EI” or “Company”) (NASDAQ GSM: EMITF) announced today following its previous announcements dated October 12, 2014 and October 27, 2014, that its wholly owned subsidiary Elbit Fashion Ltd. (“Elbit Fashion”) and Fox-Wisel Ltd. ("Fox") have completed the sale of the operation and business of "Mango" retail stores in Israel from Elbit Fashion to Fox (the “Closing”), for consideration of approximately NIS 37.7 million, out of which NIS 4.9 million were deposited in escrow, subject to certain adjustments in accordance with the provisions of the transaction documents. Following the Closing and consummation of the transaction, Elbit Fashion has ceased to operate the "Mango" retail stores activity, and accordingly the said activity shall be classified as discontinued operation at the Company's financial statements.
Jo, the ONLY person replying is you!
Please just put this troll on ignore,
maybe by some miracle she will
disappear. Thank you!
First Patient Successfully Transplanted with Cryopreserved (Frozen) NiCord® in Gamida Cell's Ongoing Phase I/II Clinical Trial for Blood Cancers
JERUSALEM, January 8, 2015 /PRNewswire/ --
Gamida Cell, a leader in cell therapy technologies and products for transplantation and adaptive immune therapy, announced today that the first person has been successfully transplanted with cryopreserved (frozen) NiCord® in the company's ongoing Phase I/II clinical study for blood cancer patients. This is the first time that a patient has been successfully transplanted with umbilical cord blood stem and progenitor cells, that were expanded (population increased) ex-vivo (outside of the body), and cryopreserved. The company also noted today that after thaw, the cryopreserved product maintained the advantage of NiCord® in demonstrating very rapid engraftment (white blood cell recovery). It is expected that this rapid engraftment will reduce the risk of opportunistic infections, will lower the morbidity associated with cord blood transplantation and shorten hospitalization.
"This is a significant technological milestone in the evolution of the development of NiCord®. Moving forward, in all ongoing and future clinical trials, NiCord® will be used only in its cryopreserved formulation. Until now, NiCord® has been transplanted as a "fresh" product that must be infused into the patient within a limited number of hours from the moment the product is released from the manufacturing site. This timetable restricted the window for transplantation for the patient. It also limited the location of manufacturing sites to the vicinity of participating medical centers and increased the cost of shipping and logistical support required from manufacturing through delivery. To overcome these limitations, Gamida Cell developed a cryopreserved formulation of the product with a long shelf life," said Dr. Yael Margolin, president and CEO of Gamida Cell.
Dr. Margolin continued, "The cryopreserved formulation of NiCord® provides several key benefits. It enables flexibility in the timing of a transplantation, which can now be determined according to the clinical conditions of the patient. If a delay is required, it is now possible and more easily managed. This flexibility in timetable also means that the product can now be distributed more efficiently and worldwide, enabling the company to expand its clinical trials to all geographic areas. NiCord® can also now be manufactured in a preferable, centralized location, which will significantly reduce the cost of goods."
NiCord® is currently manufactured and shipped to the US and Europe from Gamida Cell in Jerusalem.
NiCord® is derived from a single umbilical cord blood unit which has been expanded in culture and enriched with stem and progenitor cells using Gamida Cell's proprietary NAM technology. NiCord® is in development as an investigational therapeutic treatment for blood cancers such as leukemia and lymphoma and for non-malignant hematological diseases. Clinical sites in the US, Spain, Italy, Israel and the Netherlands will collectively enroll 20 patients, with hematologic malignancies following myeloablative therapy, in the Phase I/II study of NiCord®, in a single cord configuration. For more information about the achievements and benefits of NiCord® in a single cord configuration please click here.
This is the first time that a patient has been successfully transplanted with umbilical cord blood stem and progenitor cells, that were expanded (population increased) ex-vivo (outside of the body), and cryopreserved. The company also noted today that after thaw, the cryopreserved product maintained the advantage of NiCord® in demonstrating very rapid engraftment (white blood cell recovery).
Gamida Cell Announces Investment and Option Agreement with Major Pharmaceutical Company
Aug. 19, 2014
Jerusalem, Israel, August 19, 2014 --- Gamida Cell, a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG (“Novartis”). According to the agreement, Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord®, anticipated to be met during 2015. Completion of the transaction is subject to customary closing conditions.
Upon exercising the Option, Novartis would pay the other shareholders in Gamida Cell (the Sellers) cash payments of approximately $165 million, in accordance with the terms of the Agreement. In addition, the Sellers will be entitled to potential future payments which can reach a total of $435 million, depending on certain development and regulatory milestones and on sales of Gamida Cell's products.
Gamida Cell president and CEO Dr. Yael Margolin said, “The investment and option agreement announced today demonstrates Novartis’ belief in the potential of Gamida Cell’s platform technology, product pipeline and team. Novartis is a leading pharmaceutical company with a declared commitment to further expand and develop its pipeline of cell therapy products. This, combined with the breadth of its resources and experience, positions Novartis perfectly for an alliance with Gamida Cell.”
אני מחזיק עצמי שלא לענות לו, אבל תראה איך הוא תמיד ישאל עוד שאלה
ועוד ועוד ועוד.... פשוט להתעלם ממנו והוא יפסיק.. שים לב כמה הוא הופך אותך לנושא
של כל פוסט חדש שלו
January 16th, 2015
Top Image Systems (NASDAQ:TISA)‘s stock had its “buy” rating reaffirmed by investment analysts at Canaccord Genuity in a note issued to investors on Thursday. They currently have a $6.50 price objective on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 100.00% from the stock’s previous close.
Pluristem surges on bullish research report • 9:02 AM
Douglas W. House, SA News Ed...
Thinly-traded micro cap Pluristem Therapeutics (NASDAQ:PSTI) is up 11% premarket on robust volume in apparent response to a bullish report from Acceleron equity research with a price target of $21. It estimates EPS of $0.40 in 2017 and $1.25 in 2018.
Acceleron believes the company will make significant progress this year in its clinical pipeline including shortening the time to market for its first product, PLX cells for critical limb ischemia, currently in Phase 2 in Europe. New Adaptive Licensing legislation in the European Union allows for limited commercialization of cell therapies after a successful Phase 2 study. Pluristem has yet to disclose a timeline for approval, however.
As with any investment opportunity, retail investors should complete their own thorough due diligence before considering taking action.
Sentiment: Strong Buy
Novartis exec David Epstein says having invested in Israel's Gamida Cell
and BioLineRx, Novartis is hungry for more.
Over the past year, Novartis has invested $35 million in Israel’s Gamida Cell,
with an option to acquire it in the future for $165 million, plus royalties, by mid-2016.
The investment in Gamida Cell came from our intention to give strategic priority to
developing cell therapy and gene therapy technologies. Gamida has an advanced
stem-cell cancer treatment product.
“The investments are new. Gamida has advanced a lot since we met, the team is
(Those are a few excerpts from the globes newspaper article)
Novartis exec David Epstein says having invested in Israel's Gamida Cell and BioLineRx,
Novartis is hungry for more. Novartis also signed a deal with BiolineRX Ltd. (Nasdaq: BLRX);
TASE:BLRX), under which BioLineRx will seek and develop Israeli technologies for Novartis.
“In addition, we wanted to find a partner that has a deep familiarity with the Israeli market - with the start-ups and with the universities in Israel, and that is why we chose BioLineRx, which has been operating in Israel for a long time, in order to better connect with opportunities in Israel.”
What is your impression of the two investments you have made so far?
“The investments are new. Gamida has advanced a lot since we met, the team is very talented. The partnership with BioLineRx is fresher, but it has a lot of openness and wonderful accessibility. So, all in all, we have had a good start, but we are still in very early stages, particularly with regards to BioLineRx.”
Are there more options on the table?
“Novartis announced that it will carry out targeted acquisitions. In Israel, it will probably be primarily through BioLineRx. Under the terms of the investment in BioLineRx, the company is meant to take the money, identify the Israeli start-ups, and then acquire the rights to develop their technologies. We will be able to buy these technologies from them, if they advance well.
(These are a few excperts from the globes newspaper article)
Analysts at Zacks have given a Outperform rating on Pluristem Therapeutics Inc. (NASDAQ:PSTI) with a rating of 1. The counter has received an average rating of 1.67 from 3 brokerage firms. 2 analysts have rated the company as a strong buy. The Counter has been rated as hold from 1 Wall Street Analysts.
Pluristem Therapeutics Inc. (NASDAQ:PSTI): According to 3 Analysts, The short term target price has been estimated at $ 3.83.The target price could deviate by a maximum of $1.26 from the forecast price. In the near term, the target price could hit a high of $5 and a low of $ 3.
Company has also disclosed other Insider Buying and Selling activities to the Exchange Commission ., According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO & Chairman of Pluristem Therapeutics Inc, Aberman Zami, had purchased 13,000 shares in a transaction dated on November 11, 2014. The transaction was executed at $2.64 per share with total amount equaling $34,320. N/A
Shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) ended the session in red amid volatile trading. The shares closed down 0.13 points or 4.14% at $3.01 with 456,314 shares getting traded. Post opening the session at $3.13, the shares hit an intraday low of $2.99 and an intraday high of $3.17 and the price vacillated in this range throughout the day. The shares had closed the previous day trading session at $3.14. The company has a market cap of $212 million and the number of outstanding shares has been calculated to be 70,528,000 shares. The 52-week high of Pluristem Therapeutics Inc. (NASDAQ:PSTI) is $4.36 and the 52-week low is $2.32.
The two press releases attached hereto were issued today, by Fiserv and Bank of the West respectively.
From the Fiserv release entitled: Move Over Selfies, Bank of the West Customers Use Their Smartphone Cameras to Pay Bills With Snap-to-Pay from Fiserv
Fiserv, Inc. today announced that Bank of the West, a $71.7 billion asset bank with locations in 22 states, has added the Snap-to-Pay™ capability to its mobile banking app.... Snap-to-Pay leverages mobile imaging technology from Top Image Systems™ (TIS™), which enables mobile devices such as smartphones and tablets to accurately capture information from documents of all types and sizes.
From the Bank of the West release entitled: Bank of the West Launches Scan to Pay, One of the First, Most Accurate and Easiest Mobile Bill Payment Features in the U.S. - New App Feature Enables Users to Add a Bill in About 30 Seconds
Bank of the West announces the availability of Scan to Pay, a new bill payment feature soft launched in its mobile app in October 2014. Customers ...can now use their smartphone camera to hover over paper bill stubs to instantly capture all bill information. Through extensive testing, Bank of the West found Scan to Pay is the most accurate service of its kind with almost no image rejections.... Customer research by the bank found that customers would be more likely to pay and receive bills on their mobile phone with a quicker and simpler experience.